APPROACHES TO CORRECT DISEASES WITH GENETICALLY MODIFIED CELLS OF HUMAN SKIN
APPROACHES TO CORRECT DISEASES WITH GENETICALLY MODIFIED CELLS OF HUMAN SKIN
批准号:
6272209
负责人:
GERALD Gene KRUEGER
金额:
$3.95万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
已结题
起止时间:
1997-12-20 至 1998-11-30
关键词:
artificial skin athymic mouse biopsy congenital ichthyosis disease /disorder model enzyme deficiency fibroblasts gene expression gene therapy genetic disorder genetic markers genetic transduction histology human tissue immunocytochemistry keratinocyte laboratory rat method development natural gene amplification nonhuman therapy evaluation radioimmunoassay skin skin disorder skin transplantation sulfatases tissue /cell culture transfection /expression vector ultrasound blood flow measurement
中文摘要
对于许多遗传疾病来说,异常基因,以及正常基因都有
英文摘要
For many genetic disorders, the abnormal, as well as the normal gene have
been defined, cloned, and expressed in vitro. These advances in molecular
genetics have made it possible to correct genetic disease by bringing the
non-defective gene into the afflicted host via somatic cells (somatic cell
gene therapy). This approach appears to be particularly suitable to
heritable skin diseases of acquired malformation and abnormal
morphogenesis, e.g., Darier's disease, xeroderma pigmentosa, epidermolysis
bullosa, and those disorders which are characterized by a deficiency of a
plasma protein, e.g., hemophilia, diabetes mellitus, etc. A central issue,
now at the forefront of the biomedical community, focuses on how best to
introduce these non-defective genes into afflicted individuals. It is our
thesis that correction by genetically modifying cells of the skin has
relatively low risk, has broad application and thus has considerable
clinical utility. We are persuaded that the feasibility, limitations and
methods for applicability can be answered preclinically by transplanting
genetically modified human skin equivalents or components thereof to
athymic rodents and by experimentally analyzing selected parameters of such
skin as a function of time.
Specific aims:
1. Development of the preclinical technology for transplanting genetically
modified skin to humans.
a. Replacing the existing epidermis of human skin grafted onto athymic
rodents with an epidermis generated from genetically modified
keratinocytes.
b. Generating a genetically modified skin-equivalent carrying normal or
genetically modified fibroblasts or keratinocytes which can be transplanted
onto athymic rodents.
c. Generating a dermal matrix impregnated with genetically modified
fibroblasts that can be placed subcutaneously in rodents, and possibly
intradermally in humans.
2. To determine the long-term functionality of skin containing these
genetically modified components; specifically the capacity for a dose
response, the production by and stability of the transfected gene, and the
effect of transfection on structure and function inherent to skin.
3. To determine whether recessive X-linked ichthyosis, can be corrected
with keratinocytes or fibroblasts transfected with the gene for steroid
sulfatase, and transplanted to athymic rodents. These experiments are
designed to define the potential and the limitations of this technology.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
UTAH PSORIASIS INITIATIVE
-
批准号:7201412
-
项目类别:
-
资助金额:$0.42万
-
财政年份:2005
-
负责人:GERALD Gene KRUEGER
-
依托单位:
Utah psoriasis initiative
-
批准号:7044762
-
项目类别:
-
资助金额:$4.37万
-
财政年份:2004
-
负责人:GERALD Gene KRUEGER
-
依托单位:
APPROACHES TO CORRECT DISEASES WITH GENETICALLY MODIFIED CELLS OF THE SKIN
-
批准号:6564701
-
项目类别:
-
资助金额:$20.41万
-
财政年份:2001
-
负责人:GERALD Gene KRUEGER
-
依托单位:
APPROACHES TO CORRECT DISEASES WITH GENETICALLY MODIFIED CELLS OF THE SKIN
-
批准号:6447071
-
项目类别:
-
资助金额:$20.41万
-
财政年份:2000
-
负责人:GERALD Gene KRUEGER
-
依托单位:
APPROACHES TO CORRECT DISEASES WITH GENETICALLY MODIFIED CELLS OF THE SKIN
-
批准号:6301971
-
项目类别:
-
资助金额:$18.8万
-
财政年份:1999
-
负责人:GERALD Gene KRUEGER
-
依托单位:
DOSE RESPONSE STUDY OF BG9273(LFA 3 & IGG1 FUSION PROTEIN)
-
批准号:6304894
-
项目类别:
-
资助金额:$0.16万
-
财政年份:1999
-
负责人:GERALD Gene KRUEGER
-
依托单位:
DOSE RESPONSE STUDY OF BG9273(LFA 3 & IGG1 FUSION PROTEIN)
-
批准号:6419491
-
项目类别:
-
资助金额:$24.81万
-
财政年份:1999
-
负责人:GERALD Gene KRUEGER
-
依托单位:
APPROACHES TO CORRECT DISEASES WITH GENETICALLY MODIFIED CELLS OF THE SKIN
-
批准号:6108603
-
项目类别:
-
资助金额:$18.8万
-
财政年份:1998
-
负责人:GERALD Gene KRUEGER
-
依托单位:
FIVE DOSE TRIAL OF ABX IL8 IN TREATMENT OF SEVERE PLAQUE PSORIASIS
-
批准号:6425943
-
项目类别:
-
资助金额:$0.16万
-
财政年份:1998
-
负责人:GERALD Gene KRUEGER
-
依托单位:
DOSE RESPONSE STUDY OF BG9273(LFA 3 & IGG1 FUSION PROTEIN)
-
批准号:6425945
-
项目类别:
-
资助金额:$0.16万
-
财政年份:1998
-
负责人:GERALD Gene KRUEGER
-
依托单位:
DOSE RESPONSE STUDY OF BG9273(LFA 3 & IGG1 FUSION PROTEIN)
-
批准号:6264242
-
项目类别:
-
资助金额:$0.16万
-
财政年份:1998
-
负责人:GERALD Gene KRUEGER
-
依托单位:
RANDOMIZED DOUBLE BLIND STUDY TO EVALUATE BIOLOGIC ACTIVITY OF BG9273
-
批准号:6114860
-
项目类别:
-
资助金额:$2.81万
-
财政年份:1998
-
负责人:GERALD Gene KRUEGER
-
依托单位:
PILOT STUDY OF THE SAFETY AND EFICACY OF ISIS 2302 ON PSORIASIS
-
批准号:6114846
-
项目类别:
-
资助金额:$2.81万
-
财政年份:1998
-
负责人:GERALD Gene KRUEGER
-
依托单位:
RANDOMIZED DOUBLE BLIND STUDY TO EVALUATE BIOLOGIC ACTIVITY OF BG9273
-
批准号:6218453
-
项目类别:
-
资助金额:$0.16万
-
财政年份:1998
-
负责人:GERALD Gene KRUEGER
-
依托单位:
PHASE II RANDOMIZED BMS 188667 IN PATIENTS WITH PSORIASIS VULGARIS
-
批准号:6114858
-
项目类别:
-
资助金额:$2.81万
-
财政年份:1998
-
负责人:GERALD Gene KRUEGER
-
依托单位:
RANDOMIZED DOUBLE BLIND STUDY TO EVALUATE BIOLOGIC ACTIVITY OF BG9273
-
批准号:6425983
-
项目类别:
-
资助金额:$0.16万
-
财政年份:1998
-
负责人:GERALD Gene KRUEGER
-
依托单位:
FIVE DOSE TRIAL OF ABX IL8 IN TREATMENT OF SEVERE PLAQUE PSORIASIS
-
批准号:6264240
-
项目类别:
-
资助金额:$0.16万
-
财政年份:1998
-
负责人:GERALD Gene KRUEGER
-
依托单位:
PHASE II RANDOMIZED BMS 188667 IN PATIENTS WITH PSORIASIS VULGARIS
-
批准号:6276093
-
项目类别:
-
资助金额:$2.66万
-
财政年份:1997
-
负责人:GERALD Gene KRUEGER
-
依托单位:
OPEN LABELED PILOT STUDY OF SAFETY AND EFFICACY OF ISIS 2302 ON PSORIASIS
-
批准号:6245960
-
项目类别:
-
资助金额:$2.15万
-
财政年份:1997
-
负责人:GERALD Gene KRUEGER
-
依托单位:
PILOT STUDY OF THE SAFETY AND EFICACY OF ISIS 2302 ON PSORIASIS
-
批准号:6276081
-
项目类别:
-
资助金额:$2.66万
-
财政年份:1997
-
负责人:GERALD Gene KRUEGER
-
依托单位:
海外基金